Next-generation direct-acting influenza therapeutics.

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Influenza viruses pose a significant global health threat, necessitating effective antiviral treatments alongside vaccines.
• Current standard-of-care involves neuraminidase inhibitors, but new therapeutic classes are crucial for managing complicated influenza and reducing mortality.
• Emerging resistance to existing antiviral drugs is a growing concern, impacting treatment efficacy.

Purpose of the Study:

• To review the current landscape of influenza therapeutics, focusing on antiviral drugs.
• To evaluate the clinical status of baloxavir marboxil, a novel endonuclease inhibitor, after its initial year of use.
• To assess direct-acting antiviral candidates in development for treating influenza, addressing the challenge of drug resistance.

Main Methods:

• Literature review of influenza therapeutics, including approved drugs and candidates in development.
• Analysis of clinical data and resistance profiles for neuraminidase inhibitors and endonuclease inhibitors.
• Evaluation of preclinical and clinical data for novel antiviral agents targeting influenza virus replication.

Main Results:

• Baloxavir marboxil, a PA endonuclease inhibitor, represents a new class of influenza therapeutics approved in 2018.
• Both neuraminidase inhibitors and the new endonuclease inhibitor class exhibit low genetic barriers to resistance, with pre-existing resistance observed.
• Resistant influenza strains remain pathogenic and transmissible, highlighting the need for next-generation therapeutics.

Conclusions:

• Developing next-generation influenza therapeutics is crucial to overcome existing drug resistance challenges.
• Baloxavir marboxil and other direct-acting antivirals show promise but require careful monitoring for resistance development.
• Continued research into novel antiviral strategies is essential for effective global influenza control.